Latest Breaking News On - Positive efficacy - Page 1 : comparemela.com

FDA Approves Avacincaptad Pegol for Geographic Atrophy

The approval is the second granted to a geographic atrophy drug that targets the complement pathway.

United statesAvacincaptad pegolIapocec david lallyKunzmannk apellisAstellas pharmaDavid lallyArshadm khananiDrug administrationSierra eye associatesAmerican society of retina specialistsApellis pharmaceuticalsIveric bioAmerican societyRetina specialistsNew england retina consultantsNew treatment

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChristine regan lindenboomJorge capapeyJosh brodskyKim hollanderHyperoxaluria foundationGlobal rare disease lead at alnylam pharmaceuticalsDrug administrationAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsEuropean medicines agencyCommittee for medicinal products human usePrimary hyperoxaluria typeLower urinary

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

United statesUnited kingdomJorge capapeyKim hollanderHyperoxaluria foundationGlobal rare disease lead at alnylam pharmaceuticalsDrug administrationAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsEuropean medicines agencyCommittee for medicinal products human usePrimary hyperoxaluria typeLower urinaryPlasma oxalate levelsAdult patients

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Fabio chianelliDevelopment agreementInternational financial reporting standardsCompany or pharmatherRisk factors in companyPharmather holdings ltdInternational congressNeither the canadian securities exchangeRegulation services providerFabio chianellichief executive officerpharmather holdings ltd telMother holdingsChief executive officerAmyotrophic lateral sclerosisLate breaking abstract presentationPositive efficacySafety data